Skip to main content

Table 3 Unadjusted incidence rates of venous thromboembolic events after cancer diagnosis among older STS patients

From: Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

 

DVTa

PEa

OTEa

N/P-Yb

Rate/1,000c (95% CI)

N/P-Yb

Rate/1,000c (95% CI)

N/P-Yb

Rate/1,000c (95% CI)

By major STS subtype

 Angiosarcoma (n = 184)

14/147

95.4 (52.1, 160.0)

<11

26.5 (7.2, 68.0)

<11

39.8 (14.6, 86.6)

 Fibrosarcoma (n = 64)

<11

72.1 (19.6, 184.5)

0

0

<11

17.6 (0.4, 97.8)

 GIST (n = 845)

94/683

137.6 (111.2, 168.4)

33/721

45.7 (31.5, 64.2)

23/730

31.5 (20.0, 47.3)

 Leiomyosarcoma (n = 264)

19/210

90.6 (54.5, 141.4)

<11

28.0 (10.3, 60.8)

<11

32.6 (13.1, 67.1)

 Liposarcoma (n = 224)

13/118

110.1 (58.6, 188.2)

<11

24.5 (5.1, 71.7)

<11

24.5 (5.0, 71.5)

 MFH (n = 184)

20/178

112.2 (68.5, 173.3)

<11

21.9 (6.0, 55.9)

<11

27.3 (8.9, 63.6)

 Nerve sheath tumor (n = 118)

15/93

160.8 (90.0, 265.3)

<11

40.7 (11.1, 104.2)

<11

49.8 (16.2, 116.3)

 Sarcoma, NOS (n = 1,422)

166/812

204.4 (174.5, 237.9)

41/862

47.5 (34.1, 64.5)

41/858

47.8 (34.3, 64.8)

By history of VTEe

 Yes

61/51

1199.2 (917.3–1540.5)

11/14

785.5 (392.3–1406.0)

30/50

599.2 (404.3–855.4)

 No

306/2,417

126.6 (112.8–141.6)

94/2,575

27.6 (24.3–31.1)

76/2,540

29.9 (23.6–37.5)

 Rate ratio (yes vs. no)d

–

9.5 (7.2–12.5)

–

21.5 (11.5–40.2)

–

20.0 (13.1–30.6)

By history of CVD eventf

 Yes

120/579

207.3 (171.9–247.9)

29/623

46.6 (31.2–66.9)

39/619

63.1 (44.8–86.2)

 No

247/1,889

130.8 (115.0–148.1)

76/1,966

38.7 (30.5–48.4)

67/1,971

34.0 (26.3–43.2)

 Rate ratio (yes vs. no)d

–

1.6 (1.3–2.0)

 

1.2 (0.8–1.8)

 

1.9 (1.3–2.8)

By disease stage

 Localized

133/1,236

107.6 (90.1–127.5)

38/1,290

29.5 (20.9–40.4)

34/1,295

26.3 (18.2–36.7)

 Regional

93/586

158.7 (128.1–194.4)

26/614

42.3 (27.7–62.1)

34/610

55.7 (38.6–77.9)

 Distant

86/380

238.9 (191.1–295.0)

25/385

65.0 (42.1–95.9)

19/387

49.1 (29.6–76.7)

 Rate ratio (regional and distant. vs. local)d

–

1.5 (1.1–1.9)

–

1.4 (0.9–2.4)

–

2.1 (1.3–3.4)

By chemotherapy

 Yes

74/324

227.9 (178.9–286.1)

20/348

57.5 (35.1–88.7)

19/346

54.9 (33.0–85.7)

 No

293/2,413

136.7 (121.5–153.3)

85/2,241

37.9 (30.3–46.9)

87/2,244

38.8 (31.1–47.8)

 Rate ratio (yes vs. no)d

–

1.7 (1.3–2.2)

–

1.5 (0.9–2.5)

 

1.4 (0.9–2.3)

By surgery of primary tumor

 Yes

247/1,976

125.0 (109.9–141.6)

72/2,065

34.9 (27.3–43.9)

76/2,064

36.8 (29.0–46.1)

 No

115/467

246.4 (203.5–295.8)

32/498

64.2 (43.9–90.7)

29/501

57.9 (38.8–83.1)

 Rate ratio (yes vs. no)d

–

0.5 (0.4–0.6)

–

0.5 (0.4–0.8)

–

0.6 (0.4–1.0)

By Primary site

 Connective/subcutaneous

136/830

163.9 (137.5–193.8)

33/877

37.6 (25.9–52.8)

37/875

42.3 (29.8–58.3)

 Digestive system

120/832

144.2 (119.5–172.4)

38/879

43.2 (30.6–59.4)

29/885

32.8 (22.0–47.1)

 Other/unknowng

111/805

137.8 (113.3–165.9)

34/833

40.8 (28.3–57.0)

40/830

48.2 (34.4–65.7)

  1. Per SEER-Medicare data use agreement, cell sizes <11 cannot be displayed, nor can estimates that could be used to derive the undisplayed numbers <11. Rate ratios are highlighted in italics.
  2. a DVT deep vein thrombosis, PE pulmonary embolism, OTE other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd–Chiari syndrome, and venous embolism/thrombosis of renal vein.
  3. b N number of VTE events, P-Y person-years.
  4. cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation (≥65 years) of STS patients. Only first VTE counted in rate estimates.
  5. dRate ratios are unadjusted.
  6. eHistory of VTE of interest in the 12 months before STS diagnosis.
  7. fHistory of CVD is defined as a history of any of the following events in the 12 months before STS diagnosis: myocardial infarction, ischemic stroke, onset congestive heart failure, angina, or TIA.
  8. gOther/unknown category includes primary sites of the breast, female genital system, other non-epithelial, respiratory system, urinary system, other sites and unknown sites.